Drug · CHEMBL600
ACETYLCYSTEINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ACETYLCYSTEINE. Drugs and targets, record CHEMBL600. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL600
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
A-cys, Acc-600, Acetadote, Airbron, Cetylev, En-cys, Fabrol, Fluimucil, Fluimucil 600, Fluimucil long, Fluimucil n, Ilube, Mucomyst, Mucosil, Mucosil-10, Mucosil-20, Oronac 600, Parvolex, Respi-nac, Siran, Solmucol, Yournac
- ChEMBL
- Other names
5052, Acetilcisteina, Acetyl cysteine, Broncholysin, Fluimicil, Fluimucetin, Mercapturic acid, N-acetyi-l-cysteine, N-acetyl-l-cysteine, NSC-111180, Oristar nalc, RK-0202, Respaire, Rk-0202, Syntemucol, Tixair
- ChEMBL
- Open Targets' highest stage
- Approval, for 5 of its 196 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases196
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 196Source Open Targets
See all 196 diseasesTrials253
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 160 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 272 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01467466 | Prevention of Serious Adverse Events Following Angiography | Phase 3 | 5,177 | 2018-11-09 | acetylcysteine | Its name | ClinicalTrials.gov |
| NCT04123405 | Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis | Phase 3 | 944 | 2021-11-19 | acetylcysteine | Its name | ClinicalTrials.gov |
| NCT00780962 | N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients | Phase 2 | 399 | 2018-01-31 | n-acetylcysteine | Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03843541 | A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions | Phase 3 | 333 | 2023-01-05 | n-acetylcysteine | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01675661 | Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment | Phase 3 | 302 | 2017-03-08 | n-acetylcysteine | Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01098032 | RenalGuard System and Contrast Media | Phase 3 | 294 | 2015-03-10 | N-acetylcysteine | Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00650091 | Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF | Phase 3 | 264 | 2015-06-02 | acetylcysteine | Its name | ClinicalTrials.gov |
| NCT00896025 | Study of N-Acetylcysteine in Acute Liver Failure (ALF) | Phase 4 | 255 | 2014-01-29 | n-acetylcysteine | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT03055377 | N-Acetylcysteine for Youth Cannabis Use Disorder | Phase 2/3 | 192 | 2024-12-17 | acetylcysteine | Its name | ClinicalTrials.gov |
| NCT00248625 | N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure | Phase 3 | 184 | 2016-07-28 | n-acetylcysteine | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
1 to 10 of 253
See all 253 trialsComparisons in its trials21
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
N-Acetylcysteine (NAC) vs Placebo: Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Oral N-Acetylcysteine With Oral Placebo. | 115 of 2,391 | 112 of 2,381 | 4,772 | NCT01467466 | Trial comparisons |
Sodium Bicarbonate vs Saline: Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Intravenous Sodium Bicarbonate With Intravenous Sodium Chloride. | 111 of 2,393 | 116 of 2,379 | 4,772 | NCT01467466 | Trial comparisons |
| N-Acetylcysteine vs Placebo: Number of Participants With Maintained Forced Vital Capacity Response | 29 of 133 | 35 of 131 | 264 | NCT00650091 | Trial comparisons |
| N-acetylcysteine vs Placebo: deaths from any cause | 0 of 98 | 0 of 94 | 192 | NCT03055377 | Trial comparisons |
| N-acetylcysteine vs Placebo: serious adverse events | 0 of 98 | 0 of 94 | 192 | NCT03055377 | Trial comparisons |
| NAC Group vs Placebo Group: The Incidence of TA-TMA. | 5 of 66 | 15 of 77 | 143 | NCT03252925 | Trial comparisons |
| NAC Group vs Placebo: deaths from any cause | 16 of 66 | 27 of 74 | 140 | NCT03252925 | Trial comparisons |
| NAC Group vs Placebo: serious adverse events | 0 of 66 | 0 of 74 | 140 | NCT03252925 | Trial comparisons |
| N-Acetylcysteine (NAC) vs Placebo: serious adverse events | 3 of 60 | 4 of 62 | 122 | NCT02707640 | Trial comparisons |
| N-acetylcysteine (NAC) vs Placebo: Number of Participants With Side Effects Attributable to the Intervention | 0 of 29 | 0 of 13 | 42 | NCT01537926 | Trial comparisons |
1 to 10 of 21
See all 21 comparisons in its trialsPapers from its trials49
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL600
GET https://conductscience.org/api/drugs/v1/CHEMBL600/diseases?page=2